Introduction: Maternal vitamin D status in pregnancy has been linked to many health outcomes in mother and offspring. A wealth of observational studies have reported on both obstetric outcomes and complications, including pre-eclampsia, gestational diabetes, mode and timing of delivery. Many foetal and childhood outcomes are also linked to vitamin D status, including measures of foetal size, body composition and skeletal mineralization, in addition to later childhood outcomes, such as asthma.
Introduction
The classical role of vitamin D is in calcium and phosphate homoeostasis, and it is widely known that severe vitamin D deficiency (VDD) can result in rickets, osteomalacia and neonatal hypocalcaemia. Clinically, neonatal hypocalcaemia can result in seizures, and has been associated with softening and thinning of the skull (craniotabes), 1 and rarely, dilated cardiomyopathy. 2 However, there is increasing evidence to suggest that VDD in pregnancy is associated with wide ranging clinical outcomes, including obstetric complications, preterm birth and adverse offspring outcomes affecting the skeletal, immune and respiratory systems. 3 As a result, a number of national and international guidelines recommend vitamin D supplementation during pregnancy or offer guidance on defining deficiency and sufficiency (Table 1) , [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] though there is considerable debate regarding the thresholds for VDD and sufficiency. Most recommend between 400 and 600 IU (10-15 µg) cholecalciferol daily throughout pregnancy, although this is not currently supported by the World Health Organization (WHO). 14 It is important to mention that the Endocrine Society recommends a safe upper limit for 25(OH)D intake in pregnancy of 10 000 IU/day for individuals over the age of 19 years at risk of VDD, though their recommendations for those not at risk remain at 600 IU/ day. 15 Here, we review the evidence basis for antenatal vitamin D supplementation to prevent obstetric complications, and the influence of vitamin D on foetal growth, with a focus on skeletal development.
Vitamin D in pregnancy: physiology and epidemiology
Vitamin D can be obtained through two pathways: via the diet or via endogenous synthesis. In the diet, it can be obtained as ergocalciferol (vitamin D 2 ) from plant sources, or cholecalciferol (vitamin D 3 ) from animal sources. However, the majority is formed endogenously within the skin from the action of ultraviolet B radiation to convert 7-dehydrocholesterol to pre-vitamin D 3 . The main circulating form, 25-hydroxyvitamin D [25(OH)D], is produced through hydroxylation of pre-vitamin D in the liver. It is found either bound to vitamin D binding protein (DBP), albumin, or in the free form, and acts as a reservoir for conversion to the active metabolite, 1,25-dihydroxyvitamin D [1, 25(OH) 2 D], primarily in the renal proximal tubular cells, but also within bone, the parathyroid gland and, in pregnancy, the placenta. The production of 1,25(OH) 2 D is regulated in response to serum calcium and has a short half-life of 4-6 h. Hepatic 25-hydroxylation, conversely, is not physiologically regulated and 25(OH)D has a half-life of~2-3 weeks. 16 Serum 25(OH)D is consequently considered the best marker of vitamin D status. 17 The main role of circulating 1,25(OH) 2 D is in calcium and phosphate homoeostasis, which occurs in conjunction with parathyroid hormone (PTH). Low serum ionized Ca 2+ stimulates PTH release, increasing renal calcium reabsorption in the distal tubule of the kidney, decreasing proximal tubule phosphate reabsorption, and increasing 1,25 (OH) 2 D synthesis. 1,25(OH) 2 D then acts on the intestinal enterocytes to increase uptake of dietary calcium, simultaneously enabling PTH induced mobilization of calcium and phosphate from bone mineral. 18 During pregnancy, significant alterations to calcium and phosphate metabolism occur, allowing the accretion of calcium within the foetal skeleton, particularly during the third trimester. 19 It is quite remarkable that during pregnancy maternal serum ionized calcium concentrations remain stable, whilst intestinal calcium absorption increases, 20, 21 and additional calcium is mobilized from the maternal skeleton. 22 [29] [30] [31] [32] Biochemically low levels of 25(OH)D are highly prevalent in pregnant women, albeit using various 25(OH)D thresholds for deficiency. Dark skin pigmentation and extensive skin covering (for example for religious or cultural reasons) are the strongest risk factors for VDD, though many Caucasian women are also deficient, particularly at higher latitudes. In a cohort of predominantly Caucasian women in the UK, 31% had a serum 25(OH)D <50 nmol/l, and 18% <25 nmol/l; 33 whilst in an ethnically more diverse UK population, 36% of women had a 25(OH)D <25 nmol/l at pregnancy booking. 34 There is some evidence to suggest that the cutoffs of <25 nmol/l as deficient and >50 nmol/l as sufficient may not be relevant to pregnancy. Uniquely in pregnancy, the conversion of 25 (Fig. 2) . Women with more 'at risk' alleles may therefore require higher supplement doses to achieve vitamin D repletion in pregnancy, which may be of interest in the future era of personalized medicine. 51 
Vitamin D and obstetric complications
Numerous observational studies report associations between 25(OH)D status in pregnancy and a variety of obstetric complications, including gestational hypertension (GHT) and pre-eclampsia (PET), gestational diabetes (GDM), and timing and mode of delivery. However, the interpretation and comparison of these studies is limited by differences in the study design (e.g. prospective cohort, case-control), the timing of 25(OH)D measurements, ranging from first trimester to delivery, the definition used for both VDD and the pregnancy or delivery outcome, and the confounding factors adjusted for.
Gestational hypertension and pre-eclampsia
Previous studies have suggested that maternal calcium status might be important in the aetiology of PET, as calcium supplementation can reduce PET risk particularly in women with low calcium intake. 52 This led to the interest in the role of calci- angiogenic factors (such as vascular endothelial growth factor, VEGF), in the human placenta. 54 The outcomes of many observational studies reporting on GHT and pre-eclampsia are conflicting, with some demonstrating an inverse association between maternal vitamin D status and the risk of pre-eclampsia [55] [56] [57] [58] [59] [60] [61] [62] [63] and others no association. 57, [64] [65] [66] [67] [68] [69] [70] [71] In recent years, there have been several published meta-analyses of the relationship between maternal vitamin D status and PET risk, providing a variety of inconsistent results. 3, 38, [72] [73] [74] [75] [76] [77] The most recent systematic review and meta-analysis, published in the BMJ in 2017, showed that vitamin D had no significant influence on the risk of GHT or pre-eclampsia. 39 In the UK Health Technology Assessment meta-analysis (Harvey et al.
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), again, no significant reduction in the risk of PET with higher vitamin D status was noted (Fig. 3 ). In contrast, Aghajafari et al. reported on nine studies in another meta-analysis of VDD and pregnancy outcomes, and showed a significant association between pre-eclampsia and 25(OH)D insufficiency compared with the comparison group, with a pooled odds ratio of 1.79 (95% CI: 1.25, 2.58). 74 However, this appeared subject to a particular analytical approach as the increased risk of PET in VDD was only observed in studies in which blood sampling was later than 16 weeks gestation and when VDD was defined as 25(OH)D <75 nmol/l and not <50 nmol/l. 74 However, a more recently published trial, VDAART, showed no significant differences in the incidence of pre-eclampsia (as a secondary outcome) in a group of pregnant women supplemented with cholecalciferol (n = 440, given 4400 IU 25(OH)D daily, and the placebo group, receiving 400 IU daily n = 436). 80 
Gestational diabetes
As in the case of PET, conflicting findings have been reported for 25(OH)D status in case-control and prospective cohort studies of GDM risk, with some 38 In the most recent meta-analysis by Roth et al., vitamin D was shown to reduce the risk of gestational diabetes (RR = 0.61, 95% CI: 0.34-0.83, 2643 participants) when all trials were included, but when only the trials meeting their strict eligibility criteria were included, no effect was seen. 39 
Caesarean delivery
There is increasing interest in the role of maternal vitamin D status in relation to mode and timing of delivery, as it has been suggested that VDD may reduce pelvic muscle strength and control. 39 on the other hand, showed no effect of vitamin D supplementation on risk of preterm birth. Health of the newborn is often of interest in trials of vitamin D supplementation in pregnancy.
In one study of 4000 IU cholecalciferol versus placebo in pregnant Pakistani women, vitamin D supplementation had no effect on maternal outcomes or birthweight or size, but did have a beneficial effect on markers of newborn health, the Apgar score, at 1 and 5 min post-delivery (eg. mean Apgar at one minute in the supplemented group 7.10 ± 0.66, versus placebo group 6.90 ± 0.50, P = 0.026). 109 In another randomized trial based in India, where women in the intervention group were given 25(OH)D supplementation according to baseline vitamin D status, a positive correlation was found between maternal vitamin D status and the Apgar Score of babies (r = 0.325, P < 0.001). 78 However, the most recent meta-analysis of 1997 individuals from five trials showed that there was no reduction in risk of admission to the neonatal intensive care unit in the offspring of mothers receiving vitamin D supplementation. 39 In all obstetric outcomes, it must be acknowledged that 25(OH)D status is primarily determined by environmental factors. Therefore, confounding and reverse causality need to be considered; in addition, differences in the covariates included in multivariate models might explain the inconsistent findings. Examples include the observation that obese individuals have lower 25(OH)D status, and a higher incidence of GDM, GHT, PET, caesarean section and preterm delivery. 110, 111 Similarly, African-American women are more likely to require delivery by Caesarean section and to experience pre-eclampsia and preterm labour. 112 Therefore, whether these relatively rare obstetric outcomes can truly be attributed to lower 25(OH)D and therefore could be prevented by vitamin D supplementation must be established through carefully designed intervention studies with large numbers of participants.
Neonatal hypocalcaemia
Symptomatic neonatal hypocalcaemia is one of the foetal outcomes most reliably associated with maternal VDD. It is rarely reported in infants of white mothers, and most commonly occurs in infants of mothers with the most profound VDD, often from ethnic and cultural groups at highest risk. 
Vitamin D and foetal development
The foetus is dependent on the mother for accretion of~30 g of calcium to enable skeletal development, and rickets has been reported in infants born to mothers with VDD. [119] [120] [121] As a result, a subclinical role for vitamin D and/or calcium in foetal growth and bone development has been considered. Interestingly, maternal supplementation with calcium alone does not appear to have beneficial effects on foetal bone mineral accrual; 122 indeed a recent study has suggested detrimental effects of maternal calcium supplementation on childhood growth in females in a Gambian population particularly accustomed to low calcium intake.
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A hypothesis is developing that vitamin D may have a role in the programming of foetal development-that is, the prevailing in-utero environment modifies later phenotype, a concept termed developmental plasticity. 124 Mixed evidence is available for the influence of vitamin D status in pregnancy and other foetal and childhood outcomes, including adiposity 95, 133, 140 lean mass and childhood asthma, 80 however, the most detailed evidence is in the realm of skeletal development, which will be the focus for the latter part of this review.
Bone development

Observational studies
Some of the earliest data to suggest that vitamin D exposure might influence in utero bone mineral accrual used season as a proxy marker of vitamin D status. Namgung et al. observed that in 71 Korean neonates, those born in summer months had 8% higher whole body bone mineral content (BMC), measured by dual energy x-ray absorptiometry (DXA), after adjustment for weight, than infants born in winter. In addition, in that cohort, neonatal 25(OH)D at delivery was positively correlated with whole body BMC. 141 In contrast, the same authors found that infants in the USA who were born in the summer had lower whole body BMC than winterborn infants. 142 The authors proposed that these differences reflect the use of vitamin D supplementation in the two populations; the uptake of supplementation is low throughout pregnancy in Korea but standard practice after the first trimester in the USA, where differences in maternal 25(OH)D by season of birth were not observed. 141 This would suggest that early pregnancy 25(OH)D status is crucial for skeletal mineralization, which is in contrast to several later studies with assessment of serum 25 (OH)D. Data from the Southampton Women's Survey mother-offspring cohort, in the UK, suggest higher neonatal BMC amongst summer than winter births (Fig. 4) . Subsequent studies have used measurements of maternal or cord blood 25(OH)D as the exposure variable. In a Canadian study, 25(OH)D was measured in venous cord blood and used to divide the infants into two groups using a cut point of 37.5 nmol/l. Whole body and femur BMC relative to body weight were significantly lower in the 18 neonates with the lower cord blood 25(OH)D, compared with 32 infants with a 25(OH)D above this cut point. 143 Similarly, Viljakainen et al., using the mean of two maternal serum 25(OH)D measurements from early pregnancy and 2 days postpartum as the assessment of maternal vitamin D status, found neonatal tibial BMC and cross-sectional area measured by peripheral quantitative computed tomography (pQCT) were 14 and 16% higher, respectively, in infants born to mothers with 25(OH)D above the median for the cohort. 144 When a subset of these children were reassessed at 14 months of age, the difference in tibial BMC was no longer present, but tibial CSA remained significantly higher in those born to mothers with higher vitamin D status in pregnancy. 145 Conversely, when 125 Gambian mother-offspring pairs were studied, no significant relationships were observed between maternal 25(OH)D at either 20 or 36 weeks of gestation and offspring whole body BMC or bone area at 2, 13 or 52 weeks of age. 135 However, in contrast to the other studies, none of the mothers had a 25(OH)D below 50 nmol/l, consistent with the hypothesis that poorer skeletal mineralization might only occur in fetuses of mothers with the lowest 25(OH)D levels. There is some evidence to suggest that these relationships persist into childhood, although study findings are less consistent than in the neonatal period. Positive relationships between maternal 25(OH)D measured in late pregnancy and offspring whole body and lumbar spine (LS) bone area, BMC and areal Bone Mineral Density (aBMD) at 9 years of age in 198 mother-offspring pairs in the Princess Anne Hospital Study (Southampton, UK) were reported by Javaid et al. 138 It was also noted that children born to women who consumed vitamin D containing supplements had higher whole body BMC and bone area, but not areal BMD, supporting the evidence for maternal vitamin D supplementation-this finding persisted after adjustment for socioeconomic status. These findings were replicated in the Southampton Women's Survey (SWS), in which 1030 mother-offspring pairs had measurement of 25(OH)D at 34 weeks of gestation and whole body less head (WBLH) and LS DXA at 6-7 years. WBLH BMC, bone area, BMD and LS BMC were all significantly lower in children born to mothers with 25(OH)D <25 nmol/l in late pregnancy, including after adjustment for maternal age, ethnicity, height, prepregnancy BMI, smoking in late pregnancy, social class, maternal educational attainment and duration of breast feeding. 146 Similarly, Zhu et al. found a positive relationship between maternal 25(OH)D status at 18 weeks gestation and bone mass in young adulthood in the Raine cohort in Western Australia. They showed, after adjustment for sex, age, height and body composition at age 20 years, maternal height and prepregnancy weight, maternal age at delivery, parity, education, ethnicity, smoking during pregnancy and season of maternal blood sampling, whole body BMC and aBMD were 2.7 and 1.7% lower at 20 years of age in offspring of mothers with 25(OH)D <50 nmol/l compared to those above this level. 147 In contrast, analyses using the UK Avon Longitudinal Study of Parents and Children (ALSPAC) cohort study do not support these findings. Initially, using 6995 mother-offspring pairs, Sayer et al. reported a positive relationship between estimated maternal UVB exposure in late pregnancy and offspring WBLH BMC, bone area and BMD at 9.9 years of age. 148 However, further analysis in a subset of 3960 of the children for whom maternal serum 25(OH)D measurement was available in the first (n = 1035), second (n = 879) or third (n = 2046) trimester did not reveal any significant associations between maternal 25(OH)D and offspring bone mineralization, 149 though collinearity of the estimated maternal UVB measurement with age at assessment might have confounded the relationships reported in the initial study. More recently, the Netherlands Generation R cohort documented inconsistent relationships between pregnancy 25(OH)D and offspring bone measures. 150 Unfortunately, the analytical models used make it difficult to conclusively compare these analyses with previous studies; 151 however, these conflicting findings from two very large cohorts demonstrate the limitations of the observational approach, and the clear necessity for testing the hypothesis that maternal pregnancy supplementation with vitamin D will lead to improved offspring bone mass in randomized controlled trial settings.
Intervention studies
In 1983, the first intervention study to assess the effect of antenatal vitamin D supplementation on offspring bone mineralization was published. In total, 64 women of Asian ethnicity living in the UK participated in a non-randomized study; 19 received a daily supplement containing 1000 IU vitamin D and calcium (of unknown strength) during the last trimester, whereas 45 received no supplementation. There was no significant difference in forearm BMC of the offspring at birth assessed using single photon absorptiometry; 152 however, the study size, lack of randomization and technology used limits the interpretation of the findings. Three more recently published studies of gestational vitamin D supplementation report on postnatal bone outcomes, of which the largest is the Maternal Vitamin D Osteoporosis Study (MAVIDOS). MAVIDOS is a randomized double-blind placebo-controlled trial of antenatal vitamin D supplementation from 14 weeks of gestation until delivery conducted in three centres in the UK, reporting a primary outcome of neonatal bone mass. 153 Overall, 1134 women with a baseline 25(OH)D between 25 and 100 nmol/l were randomized to 1000 IU/day cholecalciferol or placebo; 965 remained in the study until delivery, and 736 infants underwent DXA of the whole body and/or LS. Although there were no differences in whole body or LS BMC, bone area or aBMD between the two groups overall, a significant interaction was observed between season of birth and maternal randomization group, as shown in Fig. 5 (P for interaction for BMC 0.04). 154 Thus, whole body BMC and BMD were~9 and 5% higher, respectively, in the children born in winter to mothers randomized to cholecalciferol compared to those randomized to placebo. This effect size is substantially larger than those observed between children with and without fractures, 155 and hence if persisting into later childhood is likely to be clinically relevant, particularly if it has an impact on peak bone mass, as peak bone mass achieved is a strong predictor of osteoporosis in later life. 156 Two smaller intervention studies from India and Iran have also assessed bone mass in infants born to mothers randomized to vitamin D supplementation or placebo. Sahoo et al. randomized 300 women to three groups, which received 400 IU/day cholecalciferol daily ('placebo'), 60 000 IU cholecalciferol every 4 weeks or 60 000 IU cholecalciferol every 8 weeks from the second trimester. All women also received daily calcium supplementation, though relatively small numbers of women and children (17% of the original cohort) underwent DXA at 12-16 months of age. The children in the placebo group were significantly older at DXA scan and had higher measurements of whole body BMC and BMD, but in multivariate analysis randomization group was not a significant predictor of BMC or BMD. 157 to 28 weeks until delivery, but only 25 infants (16% of the original cohort) had DXA assessment. No significant difference in whole body BMC, BMD or bone area was found, but as with the study by Sahoo et al., the small numbers included are unlikely to have sufficient power to detect a difference in the outcomes studied.
Evidence from observational studies does therefore suggest that achieving higher levels of serum 25(OH)D in pregnancy might have beneficial effects on offspring bone development, but further highquality RCTs are required to assess this. Moreover, long-term follow up of children born to participants of these trials is required. This will enable us to determine whether any effects observed in the neonatal period, such as the effect of gestational vitamin D supplementation on increased bone mineralization in children born in winter, does persist beyond the neonatal period and whether this can influence peak bone mass obtained.
Maternal pregnancy vitamin D status, epigenetics and developmental plasticity
An individual's skeletal health, most often described by measurement of BMD and BMC by DXA, is only partly explained by genetic factors [159] [160] [161] and there is increasing evidence that some of the residual variance in both BMD and fracture risk in adulthood might be explained by the influence of the environment on gene expression, both in utero and in early life. 162 Evidence is accumulating that this concept of developmental plasticity may apply in the case of the actions of vitamin D in utero on the developing foetus directly, or indirectly. It is widely recognized that genes effectively provide a library of information that can be read (expressed) differently in different cells and tissues according to function and need. Thus, in a single organism, although the genetic code contained in every somatic cell is the same, the genes expressed will vary widely from organ to organ and even from cell to cell, often in response to environmental cues 124 -so a single genotype can give rise to many different phenotypes. Various experimental studies have clearly demonstrated that alterations to maternal dietary factors during pregnancy may lead to changes in offspring phenotype and gene expression. 163, 164 These effects are likely to be underpinned by epigenetic mechanisms, processes by which gene expression is modified but without changes in the DNA code itself. Such epigenetic signals are essential in determining when and where genes are expressed. An understanding of these epigenetic processes has the potential to enable early intervention strategies to improve early development and later health; consequently the study of epigenetic biomarkers is a rapidly advancing field.
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Epigenetic mechanisms include DNA methylation, histone modification and non-coding RNAs, the most widely studies of which is DNA methylation, the transfer of a methyl group to a particular genomic location, usually at the 5′ carbon position of cytosine adjacent to a guanine base, or CpG site. A CpG site can either be methylated or unmethylated in an individual cell, however, across a whole tissue where genes in cells may be methylated or unmethylated, a range of graded gene expression from 0 to 100% is possible. 124 Methylation at regions of the genome particularly rich in CpG sites, for example, at the 5′ end of genes in regions known as CpG islands, often near to the promoter of a gene, may have important influences on that gene's expression. 124, 166, 167 In terms of the links between maternal 25(OH)D status and offspring bone mass, there is evidence that this association may be mediated partly through umbilical cord calcium concentrations, and expression of a particular active placental calcium transporter was positively associated with neonatal bone mass, 168 and with 1,25(OH) 2 -vitamin D implicated in experimental studies. 169 There is increasing evidence that epigenetic mechanisms such as DNA methylation may underlie such observations. 124, 170 In the SWS, perinatal DNA methylation at two loci of interest, CDKN2A, a key element in cell senescence 171 and the retinoid-Xreceptor-A(RXRA) gene were inversely associated with childhood BMC corrected for body size at 4 years. 172, 173 RXRA forms a heterodimer with the vitamin D receptor and is essential in the nuclear action of 1,25(OH) 2 -vitamin D. Methylation at one CpG site was related to an estimate of free 25(OH)D (Fig. 6 ). Further analyses are ongoing to establish the influence of maternal 25(OH)D on methylation of RXRA in a randomized controlled trial setting, MAVIDOS. In order to fully exploit these findings, it is essential to establish whether these associations persist into older childhood, to refine the bone phenotype, and to experimentally validate whether gestational supplementation with vitamin D might alter DNA methylation. In this section, we have mainly focussed on epigenetic mechanisms associating vitamin D status in pregnancy with offspring bone health. Research is ongoing into the links between maternal vitamin D and its influence on multiple developing body systems within the foetus, for example, immunity and allergy, as investigated in the VDAART trial, 174 and in maternal health, such as vascular pregnancy complications. 54 
Conclusions and knowledge gaps
Our understanding of the role of vitamin D during pregnancy and its role in maternal and offspring health has improved considerably over the last decade, though there is still a great deal of work to do. The UK Department of Health currently recommends routine antenatal vitamin D supplementation with 400 IU cholecalciferol daily throughout pregnancy for all women, independent of ethnicity and other risk factors for VDD. 175 There is good evidence to suggest that supplementation is important in reducing the risk of neonatal hypocalcaemia and increasing neonatal 25(OH)D status. There is evidence to suggest that certain maternal characteristics, including genetic factors, influence an individual's response to supplementation, though currently these are not usually taken into account when advising on whether a higher level supplementation is necessary for particular individuals. Further research into this and into the way in which vitamin D status tracks through pregnancy, would aid in dosing recommendations. Avoidance of vitamin D toxicity by over-supplementation, which could cause harm, is also important-the Institute of Medicine suggests that toxic effects can occur above the threshold of 125 nmol/l, and recommend avoidance of intakes above 4000 IU/day. In terms of obstetric outcomes, there is mixed and conflicting evidence on the benefits of vitamin D supplementation in pregnancy. As 25(OH)D status is primarily determined by environmental factors, confounding and reverse causality need to be considered when evaluating obstetric studies; in addition, differences in covariates included in multivariate models might explain the inconsistent findings. Whether these relatively rare obstetric outcomes can truly be attributed to lower 25(OH)D must be established through carefully designed intervention studies.
There is some evidence to support a positive relationship between vitamin D status and offspring birthweight and offspring bone mass, but conflicting evidence still exists. Intervention studies point towards a role for vitamin D in these offspring health outcomes, particularly in women who are deficient or borderline deficient in vitamin D. Research is ongoing into the mechanism by which vitamin D may be important in developmental programming of later diseases, such as osteoporosis. The programming hypothesis may present a potential approach to targeting and reducing the burden of diseases with a developmental origin across a population, rather than an individual level. Doubleblinded RCTs with a lengthy follow-up periods, such as MAVIDOS, are required to further establish the associations between vitamin D status in pregnancy and offspring health. To guide future policy, research should evaluate several important factors. These include whether serum 25(OH)D levels improve maternal and offspring outcomes in populations with different diets or skin pigmentation, establish the timing of initiation of therapy and its most effective and safe dosage, and inform whether critical periods in pregnancy exist in the role of vitamin D and its impact on the future health of both mother and offspring. Experimental techniques, including epigenetic analyses, will be important in clarifying these underlying mechanisms.
